SillaJen, Inc.
Clinical trials sponsored by SillaJen, Inc., explained in plain language.
A biopharmaceutical company developing oncolytic virus immunotherapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug BAL0891 enters human trials for Tough-to-Treat cancers Results expected Dec 2026 (estimated)
-
Cancer-Killing virus plus immunotherapy shows promise in kidney cancer trial
Disease control CompletedThis study tested a combination of two experimental treatments for people with advanced kidney cancer that cannot be removed by surgery. The first is Pexa-Vec, a modified virus designed to infect and destroy cancer cells while also boosting the immune system. The second is cemipl…
Phase 1/2 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Virus therapy takes on liver cancer in major trial
Disease control CompletedThis study tested whether adding a virus-based immunotherapy (Pexa-Vec) to the standard drug sorafenib helps people with advanced liver cancer live longer. About 459 adults with advanced liver cancer who had not received prior treatment took part. The approach uses a modified vir…
Phase 3 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC